Drug Innovators' Outlook On Innovative Treatments
Source: ISR Reports
In Q32021, ISR asked 134 outsourcers of biologic drug substance to provide a little insight into their pipelines and how that might impact their outsourcing practices. Two-thirds (63%) of respondents agree – strongly agree that their company’s focus on new, innovative treatments will impact their outsourcing practices. Roughly one-third of respondents confirmed ADC (37%) and CAR-T (30%) therapies are areas of focus.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more